{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T08:15:09Z","timestamp":1784880909694,"version":"3.55.0"},"reference-count":83,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2013]]},"DOI":"10.1248\/bpb.b13-00317","type":"journal-article","created":{"date-parts":[[2013,8,31]],"date-time":"2013-08-31T23:08:50Z","timestamp":1377990530000},"page":"1410-1415","source":"Crossref","is-referenced-by-count":27,"title":["5-Hydroxytryptamine Receptors as Targets for Drug Therapies of Vascular-Related Diseases"],"prefix":"10.1248","volume":"36","author":[{"given":"Shuji","family":"Gamoh","sequence":"first","affiliation":[{"name":"First Department of Pharmacology, Graduate School of Clinical Pharmacy, Kyushu University of Health and Welfare"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Hisa","sequence":"additional","affiliation":[{"name":"Second Department of Pharmacology, Graduate School of Clinical Pharmacy, Kyushu University of Health and Welfare"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"First Department of Pharmacology, Graduate School of Clinical Pharmacy, Kyushu University of Health and Welfare"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Rapport MM, Green AA, Page IH. Serum vasoconstrictor (serotonin): IV. Isolation and characterization. <i>J. Biol. Chem.<\/i>, 176, 1243\u20131251 (1948)."},{"key":"2","unstructured":"2) Watts SW, Morrison SF, Davis RP, Barman SM. Serotonin and blood pressure regulation. <i>Pharmacol. Rev.<\/i>, 64, 359\u2013388 (2012)."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Gershon MD, Tack J. The serotonin signalling system: from basic understanding to drug development for functional GI disorders. <i>Gastroenterology<\/i>, 132, 397\u2013414 (2007).","DOI":"10.1053\/j.gastro.2006.11.002"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Jedlitschky G, Greinacher A, Kroemer HK. Transporters in human platelets: physiologic function and impact for pharmacotherapy. <i>Blood<\/i>, 119, 3394\u20133402 (2012).","DOI":"10.1182\/blood-2011-09-336933"},{"key":"5","unstructured":"5) Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. <i>Circ. J.<\/i>, 74, 597\u2013607 (2010)."},{"key":"6","unstructured":"6) Berger M, Gray JA, Roth BL. The expanded biology of serotonin. <i>Annu. Rev. Med.<\/i>, 60, 355\u2013366 (2009)."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Maricq AV, Peterson AS, Brake AJ, Myers RM, Julius D. Primary structure and functional expression of the 5-HT<sub>3<\/sub> receptor, a serotonin-gated ion channel. <i>Science<\/i>, 254, 432\u2013437 (1991).","DOI":"10.1126\/science.1718042"},{"key":"8","unstructured":"8) Kroeze WK, Kristiansen K, Roth BL. Molecular biology of serotonin receptors structure and function at the molecular level. <i>Curr. Top. Med. Chem.<\/i>, 2, 507\u2013528 (2002)."},{"key":"9","unstructured":"9) Kaumann AJ, Levy FO. 5-Hydroxytryptamine receptors in the human cardiovascular system. <i>Pharmacol. Ther.<\/i>, 111, 674\u2013706 (2006)."},{"key":"10","unstructured":"10) Monassier L, Laplante MA, Ayadi T, Doly S, Maroteaux L. Contribution of gene-modified mice and rats to our understanding of the cardiovascular pharmacology of serotonin. <i>Pharmacol. Ther.<\/i>, 128, 559\u2013567 (2010)."},{"key":"11","unstructured":"11) Kov\u00e1cs A, H\u00e1rsing LG Jr, Sz\u00e9n\u00e1si G, Kov\u00e1cs A, H\u00e1rsing LG Jr, Sz\u00e9n\u00e1si G. Vasoconstrictor 5-HT receptors in the smooth muscle of the rat middle cerebral artery. <i>Eur. J. Pharmacol.<\/i>, 689, 160\u2013164 (2012)."},{"key":"12","unstructured":"12) Raymond JR, Mukhin YV, Gelasco A, Turner J, Collinsworth G, Gettys TW, Grewal JS, Garnovskaya MN. Multiplicity of mechanisms of serotonin receptor signal transduction. <i>Pharmacol. Ther.<\/i>, 92, 179\u2013212 (2001)."},{"key":"13","unstructured":"13) Baxter G, Kennett G, Blaney F, Blackburn T. 5-HT<sub>2<\/sub> receptor subtypes: a family re-united? <i>Trends Pharmacol. Sci.<\/i>, 16, 105\u2013110 (1995)."},{"key":"14","unstructured":"14) Engel G, G\u00f6thert M, Hoyer D, Schlicker E, Hillenbrand K. Identity of inhibitory presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT<sub>1B<\/sub> binding sites. <i>Naunyn Schmiedebergs Arch. Pharmacol.<\/i>, 332, 1\u20137 (1986)."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Barnes NM, Sharp T. A review of central 5-HT receptors and their function. <i>Neuropharmacology<\/i>, 38, 1083\u20131152 (1999).","DOI":"10.1016\/S0028-3908(99)00010-6"},{"key":"16","unstructured":"16) Nilsson T, Longmore J, Shaw D, Pantev E, Bard JA, Branchek T, Edvinsson L. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. <i>Eur. J. Pharmacol.<\/i>, 372, 49\u201356 (1999)."},{"key":"17","unstructured":"17) Morecroft I, Heeley RP, Prentice HM, Kirk A, MacLean MR. 5-Hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: importance of the 5-HT<sub>1B<\/sub> receptor. <i>Br. J. Pharmacol.<\/i>, 128, 730\u2013734 (1999)."},{"key":"18","unstructured":"18) Nilsson T, Longmore J, Shaw D, Olesen IJ, Edvinsson L. Contractile 5-HT<sub>1B<\/sub> receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry. <i>Br. J. Pharmacol.<\/i>, 128, 1133\u20131140 (1999)."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Banes AK, Watts SW. Enhanced contraction to 5-hydroxytryptamine is not due to \u201cunmasking\u201d of 5-hydroxytryptamine<sub>1b<\/sub> receptors in the mesenteric artery of the deoxycorticosterone acetate-salt rat. <i>Hypertension<\/i>, 38, 891\u2013895 (2001).","DOI":"10.1161\/hy1001.091779"},{"key":"20","unstructured":"20) Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. <i>Pharmacol. Biochem. Behav.<\/i>, 71, 533\u2013554 (2002)."},{"key":"21","unstructured":"21) Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). <i>Pharmacol. Rev.<\/i>, 46, 157\u2013203 (1994)."},{"key":"22","unstructured":"22) Sagi SA, Seasholtz TM, Kobiashvili M, Wilson BA, Toksoz D, Brown JH. Physical and functional interactions of Galphaq with Rho and its exchange factors. <i>J. Biol. Chem.<\/i>, 276, 15445\u201315452 (2001)."},{"key":"23","unstructured":"23) Rojas RJ, Yohe ME, Gershburg S, Kawano T, Kozasa T, Sondek J. Galphaq directly activates p63RhoGEF and Trio <i>via<\/i> a conserved extension of the Dbl homology-associated pleckstrin homology domain. <i>J. Biol. Chem.<\/i>, 282, 29201\u201329210 (2007)."},{"key":"24","unstructured":"24) Matsuo Y, Kuwabara M, Tanaka-Totoribe N, Kanai T, Nakamura E, Gamoh S, Suzuki A, Asada Y, Hisa H, Yamamoto R. The defective protein level of myosin light chain phosphatase (MLCP) in the isolated saphenous vein, as a vascular conduit in coronary artery bypass grafting (CABG), harvested from patients with diabetes mellitus (DM). <i>Biochem. Biophys. Res. Commun.<\/i>, 412, 323\u2013327 (2011)."},{"key":"25","unstructured":"25) Ullmer C, Schmuck K, Kalkman HO, L\u00fcbbert H. Expression of serotonin receptor mRNAs in blood vessels. <i>FEBS Lett.<\/i>, 370, 215\u2013221 (1995)."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Delaney C, Gien J, Grover TR, Roe G, Abman SH. Pulmonary vascular effects of serotonin and selective serotonin reuptake inhibitors in the late-gestation ovine fetus. <i>Am. J. Physiol. Lung Cell. Mol. Physiol.<\/i>, 301, L937\u2013L944 (2011).","DOI":"10.1152\/ajplung.00198.2011"},{"key":"27","unstructured":"27) Calama E, Garc\u00eda M, Jarque MJ, Mor\u00e1n A, Mart\u00edn ML, San Rom\u00e1n L. 5-Hydroxytryptamine-induced vasodilator responses in the hindquarters of the anaesthetized rat, involve \u03b2<sub>2<\/sub>-adrenoceptors. <i>J. Pharm. Pharmacol.<\/i>, 55, 1371\u20131378 (2003)."},{"key":"28","unstructured":"28) Diaz J, Ni W, Thompson J, King A, Fink GD, Watts SW. 5-Hydroxytryptamine lowers blood pressure in normotensive and hypertensive rats. <i>J. Pharmacol. Exp. Ther.<\/i>, 325, 1031\u20131038 (2008)."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Saxena PR, Villal\u00f3n CM. Cardiovascular effects of serotonin agonists and antagonists. <i>J. Cardiovasc. Pharmacol.<\/i>, 15 (Suppl. 7), S17\u2013S34 (1990).","DOI":"10.1097\/00005344-199000157-00004"},{"key":"30","unstructured":"30) Shoji T, Tamaki T, Fukui K, Iwao H, Abe Y. Renal hemodynamic responses to 5-hydroxytryptamine (5-HT): involvement of the 5-HT receptor subtypes in the canine kidney. <i>Eur. J. Pharmacol.<\/i>, 171, 219\u2013228 (1989)."},{"key":"31","unstructured":"31) Takahashi T, Hisa H, Satoh S. Serotonin-induced renin release in the dog kidney. <i>Eur. J. Pharmacol.<\/i>, 193, 315\u2013320 (1991)."},{"key":"32","unstructured":"32) Takahashi T, Hisa H, Satoh S. Serotonin-induced vasoconstriction in dog kidney. <i>J. Cardiovasc. Pharmacol.<\/i>, 20, 779\u2013784 (1992)."},{"key":"33","unstructured":"33) Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF; AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. <i>Neurology<\/i>, 68, 343\u2013349 (2007)."},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. <i>Cephalalgia<\/i>, 17, 15\u201322 (1997).","DOI":"10.1046\/j.1468-2982.1997.1701015.x"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Radtke A, Neuhauser H. Low rate of self-awareness and medical recognition of migraine in Germany. <i>Cephalalgia<\/i>, 32, 1023\u20131030 (2012).","DOI":"10.1177\/0333102412454945"},{"key":"36","unstructured":"36) Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia (2004)"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Tfelt-Hansen PC, Olesen J. The 5-HT<sub>1F<\/sub> receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials. <i>J. Headache Pain<\/i>, 13, 271\u2013275 (2012).","DOI":"10.1007\/s10194-012-0428-7"},{"key":"38","unstructured":"38) Olesen J, Burstein R, Ashina M, Tfelt-Hansen P. Origin of pain in migraine: evidence for peripheral sensitisation. <i>Lancet Neurol.<\/i>, 8, 679\u2013690 (2009)."},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Shevel E. The extracranial vascular theory of migraine\u2014a great story confirmed by the facts. <i>Headache<\/i>, 51, 409\u2013417 (2011).","DOI":"10.1111\/j.1526-4610.2011.01844.x"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) van den Broek RWM, Bhalla P, Maassen VanDenBrink A, de Vries R, Sharma HS, Saxena PR. Characterization of sumatriptan-induced contractions in human isolated blood vessels using selective 5-HT<sub>1B<\/sub> and 5-HT<sub>1D<\/sub> receptor antagonists and <i>in situ<\/i> hybridization. <i>Cephalalgia<\/i>, 22, 83\u201393 (2002).","DOI":"10.1046\/j.1468-2982.2002.00295.x"},{"key":"41","unstructured":"41) Mu\u00f1oz-Islas E, Lozano-Cuenca J, Gonz\u00e1lez-Hern\u00e1ndez A, Ram\u00edrez-Rosas MB, S\u00e1nchez-L\u00f3pez A, Centuri\u00f3n D, Maassenvandenbrink A, Villal\u00f3n CM. Spinal sumatriptan inhibits capsaicin-induced canine external carotid vasodilatation <i>via<\/i> 5-HT<sub>1B<\/sub> rather than 5-HT<sub>1D<\/sub> receptors. <i>Eur. J. Pharmacol.<\/i>, 615, 133\u2013138 (2009)."},{"key":"42","unstructured":"42) Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. <i>Nat. Rev. Neurol.<\/i>, 6, 573\u2013582 (2010)."},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Silberstein SD. Emerging target-based paradigms to prevent and treat migraine. <i>Clin. Pharmacol. Ther.<\/i>, 93, 78\u201385 (2013).","DOI":"10.1038\/clpt.2012.198"},{"key":"44","unstructured":"44) Knyih\u00e1r-Csillik E, Tajti J, Samsam M, S\u00e1ry G, Slez\u00e1k S, V\u00e9csei L. Effect of a serotonin agonist (sumatriptan) on the peptidergic innervation of the rat cerebral dura mater and on the expression of c-fos in the caudal trigeminal nucleus in an experimental migraine model. <i>J. Neurosci. Res.<\/i>, 48, 449\u2013464 (1997)."},{"key":"45","unstructured":"45) Potrebic S, Ahn AH, Skinner K, Fields HL, Basbaum AI. Peptidergic nociceptors of both trigeminal and dorsal root ganglia express serotonin 1D receptors: implications for the selective antimigraine action of triptans. <i>J. Neurosci.<\/i>, 23, 10988\u201310997 (2003)."},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Adham N, Bard JA, Zgombick JM, Durkin MM, Kucharewicz S, Weinshank RL, Branchek TA. Cloning and characterization of the guinea pig 5-HT<sub>1F<\/sub> receptor subtype: a comparison of the pharmacological profile to the human species homolog. <i>Neuropharmacology<\/i>, 36, 569\u2013576 (1997).","DOI":"10.1016\/S0028-3908(97)00020-8"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Nelson DL, Phebus LA, Johnson KW, Wainscott DB, Cohen ML, Calligaro DO, Xu YC. Preclinical pharmacological profile of the selective 5-HT<sub>1F<\/sub> receptor agonist lasmiditan. <i>Cephalalgia<\/i>, 30, 1159\u20131169 (2010).","DOI":"10.1177\/0333102410370873"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Tietjen EG. Migraine and ischaemic heart disease and stroke: potential mechanisms and treatment implications. <i>Cephalalgia<\/i>, 27, 981\u2013987 (2007).","DOI":"10.1111\/j.1468-2982.2007.01407.x"},{"key":"49","unstructured":"49) Farber HW, Loscalzo J. Pulmonary arterial hypertension. <i>N. Engl. J. Med.<\/i>, 351, 1655\u20131665 (2004)."},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. <i>Circulation<\/i>, 109, 159\u2013165 (2004).","DOI":"10.1161\/01.CIR.0000102381.57477.50"},{"key":"51","unstructured":"51) Herv\u00e9 P, Launay JM, Scrobohaci ML, Brenot F, Simonneau G, Petitpretz P, Poubeau P, Cerrina J, Duroux P, Drouet L, Herv\u00e9 P, Launay JM, Scrobohaci ML, Brenot F, Simonneau G, Petitpretz P, Poubeau P, Cerrina J, Duroux P, Drouet L. Increased plasma serotonin in primary pulmonary hypertension. <i>Am. J. Med.<\/i>, 99, 249\u2013254 (1995)."},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Lee SL, Wang WW, Fanburg BL. Association of Tyr phosphorylation of GTPase-activating protein with mitogenic action of serotonin. <i>Am. J. Physiol.<\/i>, 272, C223\u2013C230 (1997).","DOI":"10.1152\/ajpcell.1997.272.1.C223"},{"key":"53","unstructured":"53) Fanburg BL, Lee SL. A role for the serotonin transporter in hypoxia-induced pulmonary hypertension. <i>J. Clin. Invest.<\/i>, 105, 1521\u20131523 (2000)."},{"key":"54","unstructured":"54) MacLean MR, Sweeney G, Baird M, McCulloch KM, Houslay M, Morecroft I. 5-Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats. <i>Br. J. Pharmacol.<\/i>, 119, 917\u2013930 (1996)."},{"key":"55","unstructured":"55) Hironaka E, Hongo M, Sakai A, Mawatari E, Terasawa F, Okumura N, Yamazaki A, Ushiyama Y, Yazaki Y, Kinoshita O. Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. <i>Cardiovasc. Res.<\/i>, 60, 692\u2013699 (2003)."},{"key":"56","unstructured":"56) Baliga RS, MacAllister RJ, Hobbs AJ. New perspectives for the treatment of pulmonary hypertension. <i>Br. J. Pharmacol.<\/i>, 163, 125\u2013140 (2011)."},{"key":"57","unstructured":"57) Lawrie A, Spiekerkoetter E, Martinez EC, Ambartsumian N, Sheward WJ, MacLean MR, Harmar AJ, Schmidt AM, Lukanidin E, Rabinovitch M. Interdependent serotonin transporter and receptor pathways regulate S100A4\/Mts1, a gene associated with pulmonary vascular disease. <i>Circ. Res.<\/i>, 97, 227\u2013235 (2005)."},{"key":"58","unstructured":"58) Lopes RD, Hafley GE, Allen KB, Ferguson TB, Peterson ED, Harrington RA, Mehta RH, Gibson CM, Mack MJ, Kouchoukos NT, Califf RM, Alexander JH. Endoscopic <i>versus<\/i> open vein-graft harvesting in coronary-artery bypass surgery. <i>N. Engl. J. Med.<\/i>, 361, 235\u2013244 (2009)."},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. <i>Circulation<\/i>, 97, 916\u2013931 (1998).","DOI":"10.1161\/01.CIR.97.9.916"},{"key":"60","unstructured":"60) Miyata K, Shimokawa H, Higo T, Yamawaki T, Katsumata N, Kandabashi T, Tanaka E, Takamura Y, Yogo K, Egashira K, Takeshita A. Sarpogrelate, a selective 5-HT<sub>2A<\/sub> serotonergic receptor antagonist, inhibits serotonin-induced coronary artery spasm in a porcine model. <i>J. Cardiovasc. Pharmacol.<\/i>, 35, 294\u2013301 (2000)."},{"key":"61","unstructured":"61) Thatte HS, Khuri SF. The coronary artery bypass conduit: I. Intraoperative endothelial injury and its implication on graft patency. <i>Ann. Thorac. Surg.<\/i>, 72, S2245\u2013S2252, discussion, S2267\u2013S2270 (2001)."},{"key":"62","unstructured":"62) Nakamura E, Tanaka N, Kuwabara M, Yamashita A, Matsuo Y, Kanai T, Onitsuka T, Asada Y, Hisa H, Yamamoto R. Relative contributions of 5-hydroxytryptamine (5-HT) receptor subtypes in 5-HT-induced vasoconstriction of the distended human saphenous vein as a coronary artery bypass graft. <i>Biol. Pharm. Bull.<\/i>, 34, 82\u201386 (2011)."},{"key":"63","unstructured":"63) Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. <i>N. Engl. J. Med.<\/i>, 339, 229\u2013234 (1998)."},{"key":"64","unstructured":"64) Papa G, Degano C, Iurato MP, Licciardello C, Maiorana R, Finocchiaro C. Macrovascular complication phenotypes in type 2 diabetic patients. <i>Cardiovasc. Diabetol.<\/i>, 12, 20 (2013)."},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Brun E, Nelson RG, Bennett PH, Imperatore G, Zoppini G, Verlato G, Muggeo M; Verona Diabetes Study. Diabetes duration and cause-specific mortality in the Verona Diabetes Study. <i>Diabetes Care<\/i>, 23, 1119\u20131123 (2000).","DOI":"10.2337\/diacare.23.8.1119"},{"key":"66","unstructured":"66) Whang W, Bigger JT Jr; The CABG Patch Trial Investigators and Coordinators. Diabetes and outcomes of coronary artery bypass graft surgery in patients with severe left ventricular dysfunction: results from The CABG Patch Trial database. The CABG Patch Trial Investigators and Coordinators. <i>J. Am. Coll. Cardiol.<\/i>, 36, 1166\u20131172 (2000)."},{"key":"67","unstructured":"67) Cohen Y, Raz I, Merin G, Mozes B; Israeli Coronary Artery Bypass (ISCAB) Study Consortium. Comparison of factors associated with 30-day mortality after coronary artery bypass grafting in patients with <i>versus<\/i> without diabetes mellitus. Israeli Coronary Artery Bypass (ISCAB) Study Consortium. <i>Am. J. Cardiol.<\/i>, 81, 7\u201311 (1998)."},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Lorusso R, Pentiricci S, Raddino R, Scarabelli TM, Zambelli C, Villanacci V, Burattin A, Romanelli G, Casari S, Scelsi R, Giustina A. Influence of type 2 diabetes on functional and structural properties of coronary artery bypass conduits. <i>Diabetes<\/i>, 52, 2814\u20132820 (2003).","DOI":"10.2337\/diabetes.52.11.2814"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Mizuno Y, Isotani E, Huang J, Ding H, Stull JT, Kamm KE. Myosin light chain kinase activation and calcium sensitization in smooth muscle <i>in vivo.<\/i> <i>Am. J. Physiol. Cell Physiol.<\/i>, 295, C358\u2013C364 (2008).","DOI":"10.1152\/ajpcell.90645.2007"},{"key":"70","unstructured":"70) Woodsome TP, Eto M, Everett A, Brautigan DL, Kitazawa T. Expression of CPI-17 and myosin phosphatase correlates with Ca<sup>2+<\/sup> sensitivity of protein kinase C-induced contraction in rabbit smooth muscle. <i>J. Physiol.<\/i>, 535, 553\u2013564 (2001)."},{"key":"71","unstructured":"71) Kitazawa T, Eto M, Woodsome TP, Brautigan DL. Agonists trigger G protein-mediated activation of the CPI-17 inhibitor phosphoprotein of myosin light chain phosphatase to enhance vascular smooth muscle contractility. <i>J. Biol. Chem.<\/i>, 275, 9897\u20139900 (2000)."},{"key":"72","unstructured":"72) Wang Y, Zheng XR, Riddick N, Bryden M, Baur W, Zhang X, Surks HK. ROCK isoform regulation of myosin phosphatase and contractility in vascular smooth muscle cells. <i>Circ. Res.<\/i>, 104, 531\u2013540 (2009)."},{"key":"73","unstructured":"73) Begum N, Duddy N, Sandu O, Reinzie J, Ragolia L. Regulation of myosin-bound protein phosphatase by insulin in vascular smooth muscle cells: evaluation of the role of Rho kinase and phosphatidylinositol-3-kinase-dependent signaling pathways. <i>Mol. Endocrinol.<\/i>, 14, 1365\u20131376 (2000)."},{"key":"74","unstructured":"74) Morris AJ, Malbon CC. Physiological regulation of G protein-linked signaling. <i>Physiol. Rev.<\/i>, 79, 1373\u20131430 (1999)."},{"key":"75","unstructured":"75) Shumay E, Gavi S, Wang HY, Malbon CC. Trafficking of \u03b2<sub>2<\/sub>-adrenergic receptors: insulin and beta-agonists regulate internalization by distinct cytoskeletal pathways. <i>J. Cell Sci.<\/i>, 117, 593\u2013600 (2005)."},{"key":"76","unstructured":"76) Hupfeld CJ, Resnik JL, Ugi S, Olefsky JM. Insulin-induced beta-arrestin1 Ser-412 phosphorylation is a mechanism for desensitization of ERK activation by Galphai-coupled receptors. <i>J. Biol. Chem.<\/i>, 280, 1016\u20131023 (2005)."},{"key":"77","unstructured":"77) Ohkura M, Tanaka N, Kobayashi H, Wada A, Nakai J, Yamamoto R. Insulin induces internalization of the 5-HT<sub>2A<\/sub> receptor expressed in HEK293 cells. <i>Eur. J. Pharmacol.<\/i>, 518, 18\u201321 (2005)."},{"key":"78","unstructured":"78) Kanai T, Kuwabara M, Tanaka-Totoribe N, Nakamura E, Matsuo Y, Gamoh S, Suzuki A, Asada Y, Hisa H, Yamamoto R. Insulin induces internalization of the plasma membrane 5-hydroxytryptamine<sub>2A<\/sub> (5-HT<sub>2A<\/sub>) receptor in the isolated human endothelium-denuded saphenous vein <i>via<\/i> the phosphatidylinositol 3-kinase pathway. <i>J. Pharmacol. Sci.<\/i>, 118, 178\u2013185 (2012)."},{"key":"79","doi-asserted-by":"crossref","unstructured":"79) Kahn AM, Husid A, Allen JC, Seidel CL, Song T. Insulin acutely inhibits cultured vascular smooth muscle cell contraction by a nitric oxide synthase-dependent pathway. <i>Hypertension<\/i>, 30, 928\u2013933 (1997).","DOI":"10.1161\/01.HYP.30.4.928"},{"key":"80","unstructured":"80) Yasui S, Mawatari K, Kawano T, Morizumi R, Hamamoto A, Furukawa H, Koyama K, Nakamura A, Hattori A, Nakano M, Harada N, Hosaka T, Takahashi A, Oshita S, Nakaya Y. Insulin activates ATP-sensitive potassium channels <i>via<\/i> phosphatidylinositol 3-kinase in cultured vascular smooth muscle cells. <i>J. Vasc. Res.<\/i>, 45, 233\u2013243 (2008)."},{"key":"81","unstructured":"81) Timmerman KL, Lee JL, Dreyer HC, Dhanani S, Glynn EL, Fry CS, Drummond MJ, Sheffield-Moore M, Rasmussen BB, Volpi E. Insulin stimulates human skeletal muscle protein synthesis <i>via<\/i> an indirect mechanism involving endothelial-dependent vasodilation and mammalian target of rapamycin complex 1 signaling. <i>J. Clin. Endocrinol. Metab.<\/i>, 95, 3848\u20133857 (2010)."},{"key":"82","doi-asserted-by":"crossref","unstructured":"82) Baron AD, Tarshoby M, Hook G, Lazaridis EN, Cronin J, Johnson A, Steinberg HO. Interaction between insulin sensitivity and muscle perfusion on glucose uptake in human skeletal muscle: evidence for capillary recruitment. <i>Diabetes<\/i>, 49, 768\u2013774 (2000).","DOI":"10.2337\/diabetes.49.5.768"},{"key":"83","unstructured":"83) Kahn AM, Husid A, Odebunmi T, Allen JC, Seidel CL, Song T. Insulin inhibits vascular smooth muscle contraction at a site distal to intracellular Ca<sup>2+<\/sup> concentration. <i>Am. J. Physiol.<\/i>, 274, E885\u2013E892 (1998)."}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/36\/9\/36_b13-00317\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T05:21:48Z","timestamp":1615872108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/36\/9\/36_b13-00317\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":83,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b13-00317","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}